Abstract
Therapy patterns across various subgroups were examined at the end of third year (yr) in LANDMARC, a prospective observational study (CTRI/2017/05/008452), that included participants with T2D on ≥2 antihyperglycemic medications. Of 6222 evaluable participants (mean baseline values - age: 52.1 yrs, T2D duration: 8.6 yrs and A1C: 8.05%), 5273 completed 3-yr follow-up visit. Therapeutic management was at the discretion of the treating physician. At the end of the third yr, the proportion of participants taking insulin + OAD increased (baseline: 23.95%; 3-yrs: 34.86%); while those taking only OADs decreased (baseline: 74.51%; 3-yrs: 63.30%). Among injectable glucose-lowering drugs, there was an increase in basal, prandial and premix insulin. Biguanides and sulfonylureas were the most commonly used OAD classes, the highest increase in OAD addition was seen for DPP4 inhibitors (baseline: 3043/6222, 48.91%; 3-yrs: 3287/5264, 62.44%) followed by SGLT2 inhibitors (baseline: 654/6222, 10.51%; 3-yrs: 1231/5264, 23.39%). Overall, glycemic parameters improved in the insulin subgroup compared to the insulin naïve subgroup (p<0.0001). No difference in change of glycemic parameters was noted in those on basal vs. premix insulin (Table). Overall, 3-yr data indicate that timely intensification of therapy may play an important role in improving glycemic parameters. Disclosure H.Thacker: None. A.Sugumaran: Employee; Sanofi. A.Satpathy: Employee; Sanofi. A.Gadekar: Employee; Sanofi. S.K.Menon: Employee; Sanofi. R.Neogi: Employee; Sanofi. D.Chodankar: Employee; Sanofi. C.Trivedi: None. S.Wangnoo: None. A.H.Zargar: None. N.Rais: Advisory Panel; Bayer Consumer Care AG, Board Member; Abbott, Biocon. A.K.Das: n/a. S.R.Joshi: Advisory Panel; Biocon, Zydus Cadila, Torrent Pharmaceuticals Ltd, Franco India, Consultant; Glenmark Pharmaceuticals, Twin Health, Speaker's Bureau; Abbott Nutrition, Sanofi, Abbott, Novo Nordisk, Lupin Pharmaceuticals, Inc. A.Mithal: Advisory Panel; Eris Lifesciences Ltd., Consultant; Glenmark Pharmaceuticals, Lupin Pharmaceuticals, Inc., USV Private Limited, Research Support; Sanofi, Speaker's Bureau; Novo Nordisk, Boehringer-Ingelheim, AstraZeneca, Sun Pharmaceutical Industries Ltd., Novartis. S.Kalra: Speaker's Bureau; Abbott, Bayer Inc., Novo Nordisk, Sanofi. A.Unnikrishnan: Speaker's Bureau; Sanofi, AstraZeneca, Boehringer-Ingelheim, Intas Pharmaceuticals Ltd. K.Kumar: None. B.Sethi: None. S.Chowdhury: None. Funding Sanofi India
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
